In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 22625-57-6, name is 5-(Chloromethyl)oxazolidin-2-one, introducing its new discovery. Recommanded Product: 5-(Chloromethyl)oxazolidin-2-one
Described are RORgamma modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORgamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORgamma activity, for example, autoimmune and/or inflammatory disorders.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 22625-57-6, and how the biochemistry of the body works.Recommanded Product: 5-(Chloromethyl)oxazolidin-2-one
Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H1409NO – PubChem